Maxim Group analyst Jason McCarthy maintained a Buy rating on Biocept (BIOC – Research Report) yesterday and set a price target of $7.00. The company's shares closed last Thursday at $2.05, close to its 52-week low of $1.78. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -28.4% and a 16.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Monopar Therapeutics Inc. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biocept with a $7.00 average price target.
https://www.tipranks.com/news/blurbs/maxim-group-thinks-biocepts-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Jul 2022 até Ago 2022 Click aqui para mais gráficos Biocept.
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Ago 2021 até Ago 2022 Click aqui para mais gráficos Biocept.